David A. Fiellin mostly deals with Buprenorphine, Psychiatry, Anesthesia, Opioid and Substance abuse. His Buprenorphine research incorporates elements of Clinical trial, Heroin, Randomized controlled trial, Emergency medicine and Naloxone. His studies deal with areas such as Medical prescription and Public health as well as Psychiatry.
His work deals with themes such as Opioid analgesics and Naltrexone, which intersect with Anesthesia. David A. Fiellin has researched Opioid in several fields, including Cross-sectional study, Hiv status, Physical therapy, Chronic pain and Addiction. His research in Substance abuse intersects with topics in Young adult, -Naloxone, Acquired immunodeficiency syndrome and Cohort study.
The scientist’s investigation covers issues in Psychiatry, Buprenorphine, Internal medicine, Opioid and Cohort study. In his study, which falls under the umbrella issue of Psychiatry, Emergency medicine is strongly linked to Medical prescription. The Buprenorphine study combines topics in areas such as Methadone, Anesthesia, Opioid use disorder, Randomized controlled trial and Naloxone.
His Randomized controlled trial research integrates issues from Clinical trial and Abstinence. He interconnects Chronic pain and Intensive care medicine in the investigation of issues within Opioid. His work carried out in the field of Substance abuse brings together such families of science as Acquired immunodeficiency syndrome and Family medicine.
David A. Fiellin spends much of his time researching Internal medicine, Cohort study, Opioid use disorder, Opioid and Buprenorphine. The study incorporates disciplines such as Medical prescription, Poisson regression and Substance abuse in addition to Internal medicine. His Medical prescription research focuses on Emergency medicine and how it connects with Prospective cohort study.
His research integrates issues of Psychological intervention, Heroin, Emergency department and Family medicine, Referral in his study of Opioid use disorder. His studies examine the connections between Opioid and genetics, as well as such issues in Incidence, with regards to Injury prevention and Public health. His studies in Buprenorphine integrate themes in fields like Methadone, Psychiatry and Opioid Agonist.
His primary areas of investigation include Cohort study, Internal medicine, Opioid use disorder, Opioid and Viral load. The concepts of his Cohort study study are interwoven with issues in Prospective cohort study, Confidence interval, Public health, Medical prescription and Cohort. His Medical prescription research includes themes of Heroin and Emergency medicine.
His Internal medicine study combines topics in areas such as Acquired immunodeficiency syndrome and Medicaid. His Opioid use disorder study incorporates themes from Buprenorphine, Hepatitis C, Randomized controlled trial and Referral. David A. Fiellin combines subjects such as Methadone, Emergency department and Family medicine with his study of Buprenorphine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.
Bridget A. Martell;Patrick G. O'Connor;Robert D. Kerns;William C. Becker.
Annals of Internal Medicine (2007)
Screening for Alcohol Problems in Primary Care: A Systematic Review
David A. Fiellin;M. Carrington Reid;Patrick G. O'Connor.
JAMA Internal Medicine (2000)
The prevalence and impact of alcohol problems in major depression: a systematic review.
Lynn E. Sullivan;David A. Fiellin;Patrick G. O’Connor.
The American Journal of Medicine (2005)
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial
Gail D’Onofrio;Patrick G. O’Connor;Michael V. Pantalon;Marek C. Chawarski.
Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates.
William C. Becker;Lynn E. Sullivan;Jeanette M. Tetrault;Rani A. Desai.
Drug and Alcohol Dependence (2008)
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence A 2-Phase Randomized Controlled Trial
Roger D. Weiss;Jennifer Sharpe Potter;David A. Fiellin;David A. Fiellin;Marilyn Byrne;Marilyn Byrne.
Archives of General Psychiatry (2011)
Hazardous and harmful alcohol consumption in primary care.
M C Reid;D A Fiellin;P G O'Connor.
JAMA Internal Medicine (1999)
Effects of Marijuana Smoking on Pulmonary Function and Respiratory Complications: A Systematic Review
Jeanette M. Tetrault;Kristina Crothers;Brent A. Moore;Reena Mehra.
JAMA Internal Medicine (2007)
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence
David A Fiellin;Michael V Pantalon;Marek C Chawarski;Brent A Moore.
The New England Journal of Medicine (2006)
Pharmacologic Treatment of Heroin-Dependent Patients
Patrick G. O'Connor;David A. Fiellin.
Annals of Internal Medicine (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: